Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIOL BIOLASE		$0.01	$0.02 ▼ $1.94	$581K	0.67	2.58 million shs	N/A
IONM Assure	$0.05	$0.04	$0.03 ▼ $0.55	$150K	185.75	4,148 shs	140 shs
NUWE Nuwellis	$6.30 +13.7%	$9.78	$4.82 ▼ $175.98	$630K	N/A	421,659 shs	1.19 million shs
TTOO T2 Biosystems	$0.01 -45.0%	$0.09	$0.00 ▼ $4.04	$255K	0.25	523,780 shs	9,208 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIOL BIOLASE	0.00%	0.00%	-89.01%	-90.38%	-97.87%
IONM Assure	0.00%	0.00%	+65.52%	+47,900.00%	-84.41%
NUWE Nuwellis	0.00%	+6.54%	-62.57%	-86.26%	-92.87%
TTOO T2 Biosystems	0.00%	+29.41%	-71.61%	-86.63%	-99.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIOL BIOLASE	0.9044 of 5 stars	3.5	0.0	0.0	0.0	0.0	0.0	0.0
IONM Assure	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	1.6248 of 5 stars	0.0	4.0	0.0	0.0	2.3	1.7	1.3
TTOO T2 Biosystems	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIOL BIOLASE	3.00	Buy	$1.20	∞ Upside
IONM Assure	0.00	N/A	N/A	N/A
NUWE Nuwellis	3.00	Buy	N/A	N/A
TTOO T2 Biosystems	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIOL BIOLASE	$48.83M	0.00	N/A	N/A	($0.07) per share	0.00
IONM Assure	$149K	1.01	N/A	N/A	($41.04) per share	0.00
NUWE Nuwellis	$8.74M	0.07	N/A	N/A	$62.71 per share	0.10
TTOO T2 Biosystems	$7.68M	0.03	N/A	N/A	($6.91) per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIOL BIOLASE	-$20.63M	-$14.94	N/A	N/A	N/A	-41.65%	-1,782.73%	-55.31%	N/A
IONM Assure	-$26.08M	N/A	0.00	∞	N/A	-25,178.32%	N/A	-249.78%	N/A
NUWE Nuwellis	-$11.16M	-$35.36	N/A	N/A	N/A	-176.45%	-347.59%	-195.65%	N/A
TTOO T2 Biosystems	-$50.08M	N/A	0.00	∞	N/A	-563.16%	N/A	-174.06%	10/6/2025 (Estimated)

Latest IONM, BIOL, NUWE, and TTOO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	NUWE Nuwellis	-$0.45	-$60.99	-$60.54	-$60.99	$2.20 million	$1.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIOL BIOLASE	N/A	N/A	N/A	N/A	N/A
IONM Assure	N/A	N/A	N/A	N/A	N/A
NUWE Nuwellis	N/A	N/A	N/A	N/A	N/A
TTOO T2 Biosystems	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIOL BIOLASE	N/A	0.71	0.36
IONM Assure	N/A	0.20	0.20
NUWE Nuwellis	N/A	2.23	1.59
TTOO T2 Biosystems	N/A	0.40	0.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIOL BIOLASE	8.79%
IONM Assure	3.33%
NUWE Nuwellis	3.13%
TTOO T2 Biosystems	23.18%

Insider Ownership

Company	Insider Ownership
BIOL BIOLASE	0.27%
IONM Assure	3.80%
NUWE Nuwellis	20.08%
TTOO T2 Biosystems	0.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIOL BIOLASE	160	33.41 million	33.32 million	Not Optionable
IONM Assure	130	3.13 million	3.02 million	Not Optionable
NUWE Nuwellis	70	100,000	84,000	Not Optionable
TTOO T2 Biosystems	180	21.04 million	21.04 million	Optionable

IONM, BIOL, NUWE, and TTOO Headlines

Recent News About These Companies

TTOO T2 Biosystems, Inc. - Seeking Alpha

June 25, 2025 | seekingalpha.com

T2 Biosystems Inc. (TTOO) After Hours Quote

June 10, 2025 | nasdaq.com

Despite Promising Technology, Did Operational Cost Structure Take Down T2 Biosystems?

March 5, 2025 | 360dx.com3

T2 Biosystems initiates major layoffs, seeks asset sale

February 22, 2025 | uk.investing.com

Medical diagnostics firm T2 Biosystems cuts ‘substantially all’ workers

February 18, 2025 | bizjournals.com

T2 Biosystems to be delisted from Nasdaq

February 11, 2025 | msn.com

T2 Biosystems stock plunges to 52-week low of $0.22

January 30, 2025 | msn.com

T2 Biosystems Inc’s Stock Drama: Could This Be a Game-Changer for TTOO Investors?

January 24, 2025 | bovnews.comB

T2 Biosystems stock plunges to 52-week low of $0.25

January 21, 2025 | msn.com

T2 Biosystems amends loan terms, extends maturity date

January 18, 2025 | msn.com

T2 Biosystems reports preliminary Q4 revenue $2.3M

January 7, 2025 | markets.businessinsider.com

T2 Biosystems Reports Preliminary Financial Results For Q4 And Full Year 2024

January 7, 2025 | markets.businessinsider.com

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

January 7, 2025 | finance.yahoo.com

T2 Biosystems Enhances Governance and Leadership Stability

January 3, 2025 | tipranks.com

T2 Biosystems announces sale of four T2Dx Intruments to European distributor

December 18, 2024 | markets.businessinsider.com

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

December 18, 2024 | finance.yahoo.com

T2 Biosystems achieves milestone with 250,000th novel sepsis test shipped

December 17, 2024 | markets.businessinsider.com

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

December 17, 2024 | markets.businessinsider.com

T2 Biosystems extends multi-year supplier agreement with Vizient

December 16, 2024 | markets.businessinsider.com

T2 Biosystems Extends Supplier Agreement with Vizient Through March 2026 for Rapid Sepsis Detection Products

December 16, 2024 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONM, BIOL, NUWE, and TTOO Company Descriptions

BIOLASE NASDAQ:BIOL

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

Assure NASDAQ:IONM

$0.05 0.00 (0.00%)

As of 11:40 AM Eastern

Assure Holdings Corp., through its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services in the United States. It offers services in the areas of neurosurgery, spine, cardiovascular, orthopedic, ear, nose, throat, and other surgical procedures. The company delivers various clinical and operational services, including scheduling of the interoperative neurophysiologist and supervising practitioner, real time monitoring, patient advocacy, and billing services to support surgeons and medical facilities during invasive procedures. Assure Holdings Corp. is based in Englewood, Colorado.

Nuwellis NASDAQ:NUWE

$6.30 +0.76 (+13.72%)

Closing price 04:00 PM Eastern

Extended Trading

$6.36 +0.06 (+0.95%)

As of 06:44 PM Eastern

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

T2 Biosystems NASDAQ:TTOO

$0.01 -0.01 (-45.00%)

As of 11:04 AM Eastern

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time